Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1996 Oct;70(10):6557–6562. doi: 10.1128/jvi.70.10.6557-6562.1996

Proline-rich tandem repeats of antibody complementarity-determining regions bind and neutralize human immunodeficiency virus type 1 particles.

J D Fontenot 1, V R Zacharopoulos 1, D M Phillips 1
PMCID: PMC190696  PMID: 8794290

Abstract

The proline-rich tandem repeat domain of human mucin MUC1 forms an extended structure containing large repeating loops that are crested by a turn. We show that the repeating-loop structure of MUC1 can be replaced by an antibody complementarity-determining region loop of a human immunodeficiency virus type 1 (HIV-1)-specific neutralizing antibody to create a chimeric, multivalent, mucin-like, anti-HIV-1 compound. We used 8 residues of an antibody molecule to replace 8 of 20 residues of the MUC1 tandem-repeat sequence. The antiviral peptide discussed here contains three copies of a 20-residue tandem repeat, (IYYDYEEDPAPGSTAPPAHG)3, for a total of 60 residues. We demonstrate that the mucin-antibody chimera retains the binding specificity of the parent antibody (monoclonal antibody F58), GPGR of the HIV-1 gp120 V3 neutralizing epitope, and the ability to neutralize virus particles. In inhibition enzyme-linked immunosorbent assay, the mucin-antibody chimeric peptide could inhibit 71 to 84% of binding to a V3 loop peptide by monoclonal antibodies known to be specific for GPGR in the V3 loop. The mucin-antibody chimeric peptide could also inhibit monoclonal antibody binding to native gp120 captured from virus particles. In addition, the chimeric peptide neutralized the homologous HIV-IIIB virus in a standard neutralization assay. The methods of antiviral peptide design and construction presented here are general and theoretically limited only by the size of the antibody repertoire. This approach could be used to synthesize peptides for a variety of therapeutic applications.

Full Text

The Full Text of this article is available as a PDF (288.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archibald D. W., Cole G. A. In vitro inhibition of HIV-1 infectivity by human salivas. AIDS Res Hum Retroviruses. 1990 Dec;6(12):1425–1432. doi: 10.1089/aid.1990.6.1425. [DOI] [PubMed] [Google Scholar]
  2. Baba M., Pauwels R., Balzarini J., Arnout J., Desmyter J., De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A. 1988 Aug;85(16):6132–6136. doi: 10.1073/pnas.85.16.6132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barbas C. F., 3rd, Björling E., Chiodi F., Dunlop N., Cababa D., Jones T. M., Zebedee S. L., Persson M. A., Nara P. L., Norrby E. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9339–9343. doi: 10.1073/pnas.89.19.9339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Batinić D., Robey F. A. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J Biol Chem. 1992 Apr 5;267(10):6664–6671. [PubMed] [Google Scholar]
  5. Bergey E. J., Cho M. I., Blumberg B. M., Hammarskjöld M. L., Rekosh D., Epstein L. G., Levine M. J. Interaction of HIV-1 and human salivary mucins. J Acquir Immune Defic Syndr. 1994 Oct;7(10):995–1002. [PubMed] [Google Scholar]
  6. Burton D. R., Barbas C. F., 3rd, Persson M. A., Koenig S., Chanock R. M., Lerner R. A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10134–10137. doi: 10.1073/pnas.88.22.10134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Burton D. R., Pyati J., Koduri R., Sharp S. J., Thornton G. B., Parren P. W., Sawyer L. S., Hendry R. M., Dunlop N., Nara P. L. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994 Nov 11;266(5187):1024–1027. doi: 10.1126/science.7973652. [DOI] [PubMed] [Google Scholar]
  8. Carlstedt I., Lindgren H., Sheehan J. K. The macromolecular structure of human cervical-mucus glycoproteins. Studies on fragments obtained after reduction of disulphide bridges and after subsequent trypsin digestion. Biochem J. 1983 Aug 1;213(2):427–435. doi: 10.1042/bj2130427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chesebro B., Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol. 1988 Oct;62(10):3779–3788. doi: 10.1128/jvi.62.10.3779-3788.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chothia C., Lesk A. M., Tramontano A., Levitt M., Smith-Gill S. J., Air G., Sheriff S., Padlan E. A., Davies D., Tulip W. R. Conformations of immunoglobulin hypervariable regions. Nature. 1989 Dec 21;342(6252):877–883. doi: 10.1038/342877a0. [DOI] [PubMed] [Google Scholar]
  11. Chou P. Y., Fasman G. D. Empirical predictions of protein conformation. Annu Rev Biochem. 1978;47:251–276. doi: 10.1146/annurev.bi.47.070178.001343. [DOI] [PubMed] [Google Scholar]
  12. D'Souza M. P., Milman G., Bradac J. A., McPhee D., Hanson C. V., Hendry R. M. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS. 1995 Aug;9(8):867–874. doi: 10.1097/00002030-199508000-00006. [DOI] [PubMed] [Google Scholar]
  13. Fontenot J. D., Finn O. J., Dales N., Andrews P. C., Montelaro R. C. Synthesis of large multideterminant peptide immunogens using a poly-proline beta-turn helix motif. Pept Res. 1993 Nov-Dec;6(6):330–336. [PubMed] [Google Scholar]
  14. Fontenot J. D., Gatewood J. M., Mariappan S. V., Pau C. P., Parekh B. S., George J. R., Gupta G. Human immunodeficiency virus (HIV) antigens: structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins. Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):315–319. doi: 10.1073/pnas.92.1.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fontenot J. D., Mariappan S. V., Catasti P., Domenech N., Finn O. J., Gupta G. Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope. J Biomol Struct Dyn. 1995 Oct;13(2):245–260. doi: 10.1080/07391102.1995.10508837. [DOI] [PubMed] [Google Scholar]
  16. Fox P. C., Wolff A., Yeh C. K., Atkinson J. C., Baum B. J. Saliva inhibits HIV-1 infectivity. J Am Dent Assoc. 1988 May;116(6):635–637. doi: 10.14219/jada.archive.1988.0002. [DOI] [PubMed] [Google Scholar]
  17. Fultz P. N. Components of saliva inactivate human immunodeficiency virus. Lancet. 1986 Nov 22;2(8517):1215–1215. doi: 10.1016/s0140-6736(86)92218-x. [DOI] [PubMed] [Google Scholar]
  18. Gendler S., Taylor-Papadimitriou J., Duhig T., Rothbard J., Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem. 1988 Sep 15;263(26):12820–12823. [PubMed] [Google Scholar]
  19. Gorny M. K., Xu J. Y., Karwowska S., Buchbinder A., Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol. 1993 Jan 15;150(2):635–643. [PubMed] [Google Scholar]
  20. Hardingham T. E., Fosang A. J. Proteoglycans: many forms and many functions. FASEB J. 1992 Feb 1;6(3):861–870. [PubMed] [Google Scholar]
  21. Harrop H. A., Coombe D. R., Rider C. C. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS. 1994 Feb;8(2):183–192. doi: 10.1097/00002030-199402000-00005. [DOI] [PubMed] [Google Scholar]
  22. Horton R. A manifesto for microbicides. Lancet. 1993 Aug 7;342(8867):357–357. doi: 10.1016/0140-6736(93)91484-4. [DOI] [PubMed] [Google Scholar]
  23. Javaherian K., Langlois A. J., McDanal C., Ross K. L., Eckler L. I., Jellis C. L., Profy A. T., Rusche J. R., Bolognesi D. P., Putney S. D. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768–6772. doi: 10.1073/pnas.86.17.6768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kang C. Y., Brunck T. K., Kieber-Emmons T., Blalock J. E., Kohler H. Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. Science. 1988 May 20;240(4855):1034–1036. doi: 10.1126/science.3368787. [DOI] [PubMed] [Google Scholar]
  25. Laman J. D., Schellekens M. M., Lewis G. K., Moore J. P., Matthews T. J., Langedijk J. P., Meloen R. H., Boersma W. J., Claassen E. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody. AIDS Res Hum Retroviruses. 1993 Jul;9(7):605–612. doi: 10.1089/aid.1993.9.605. [DOI] [PubMed] [Google Scholar]
  26. Levi M., Sällberg M., Rudén U., Herlyn D., Maruyama H., Wigzell H., Marks J., Wahren B. A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4374–4378. doi: 10.1073/pnas.90.10.4374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Moore J. P., Jarrett R. F. Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1. AIDS Res Hum Retroviruses. 1988 Oct;4(5):369–379. doi: 10.1089/aid.1988.4.369. [DOI] [PubMed] [Google Scholar]
  28. Moore J. P. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. AIDS. 1990 Apr;4(4):297–305. doi: 10.1097/00002030-199004000-00003. [DOI] [PubMed] [Google Scholar]
  29. Nara P. L., Hatch W. C., Dunlop N. M., Robey W. G., Arthur L. O., Gonda M. A., Fischinger P. J. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses. 1987 Fall;3(3):283–302. doi: 10.1089/aid.1987.3.283. [DOI] [PubMed] [Google Scholar]
  30. Pearce-Pratt R., Phillips D. M. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol Reprod. 1996 Jan;54(1):173–182. doi: 10.1095/biolreprod54.1.173. [DOI] [PubMed] [Google Scholar]
  31. Pincus S. H., Messer K. G., Schwartz D. H., Lewis G. K., Graham B. S., Blattner W. A., Fisher G. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest. 1993 May;91(5):1987–1996. doi: 10.1172/JCI116420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Ring C. S., Kneller D. G., Langridge R., Cohen F. E. Taxonomy and conformational analysis of loops in proteins. J Mol Biol. 1992 Apr 5;224(3):685–699. doi: 10.1016/0022-2836(92)90553-v. [DOI] [PubMed] [Google Scholar]
  33. Roderiquez G., Oravecz T., Yanagishita M., Bou-Habib D. C., Mostowski H., Norcross M. A. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J Virol. 1995 Apr;69(4):2233–2239. doi: 10.1128/jvi.69.4.2233-2239.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Segal D. M., Padlan E. A., Cohen G. H., Rudikoff S., Potter M., Davies D. R. The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site. Proc Natl Acad Sci U S A. 1974 Nov;71(11):4298–4302. doi: 10.1073/pnas.71.11.4298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sheehan J. K., Oates K., Carlstedt I. Electron microscopy of cervical, gastric and bronchial mucus glycoproteins. Biochem J. 1986 Oct 1;239(1):147–153. doi: 10.1042/bj2390147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stanfield R. L., Takimoto-Kamimura M., Rini J. M., Profy A. T., Wilson I. A. Major antigen-induced domain rearrangements in an antibody. Structure. 1993 Oct 15;1(2):83–93. doi: 10.1016/0969-2126(93)90024-b. [DOI] [PubMed] [Google Scholar]
  37. Williams W. V., Guy H. R., Rubin D. H., Robey F., Myers J. N., Kieber-Emmons T., Weiner D. B., Greene M. I. Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: modeling of their three-dimensional structures. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6488–6492. doi: 10.1073/pnas.85.17.6488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Williams W. V., Kieber-Emmons T., VonFeldt J., Greene M. I., Weiner D. B. Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity. J Biol Chem. 1991 Mar 15;266(8):5182–5190. [PubMed] [Google Scholar]
  39. Yahi N., Sabatier J. M., Nickel P., Mabrouk K., Gonzalez-Scarano F., Fantini J. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. J Biol Chem. 1994 Sep 30;269(39):24349–24353. [PubMed] [Google Scholar]
  40. von Brunn A., Brand M., Reichhuber C., Morys-Wortmann C., Deinhardt F., Schödel F. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. Vaccine. 1993;11(8):817–824. doi: 10.1016/0264-410x(93)90356-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES